Ireland
--:--IST
Starting soon Observational

Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study

NCT06983795 · tracked via the Priya Life Science Singapore tracker
Phase
Observational
Started
2025-07
Last updated
2025-05-21

Condition(s) studied

Ischemic StrokePatent Foramen Ovale

Investigational drug(s) / intervention(s)

PFO closure using approved PFO closure devices, Surgical PFO closureMedical management →

PFO closure using approved PFO closure devices, Surgical PFO closure: PFO closure using approved PFO closure devices, Surgical PFO closure

Medical management: Antiplatelet therapy * ASA, also called acetylsalicylic acid (Aspirin, Asaphen, Entrophen, Novasen) * clopidogrel (Plavix) * ticagrelor (Brilinta) * dipyridamole (Persantine) * cilostazol Anticoagulation therapy * apixaban (Eliquis) * dabigatran (Pradaxa) * edoxaban (Lixiana) * rivaroxaban (Xarelto) * warfarin (Coumadin)

Study summary

A registry of patients from the Asia-Pacific region with PFO and ischemic stroke, designed to study the characteristics, investigations, treatment and outcomes using real-world data.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria 1. Subject has experienced acute ischemic stroke or transient ischemic attack 2. Subject is screened with presence of PFO (right-to-left shunt) on appropriate cardiac imaging (transthoracic echocardiography and/or transesophageal echocardiography) or transcranial Doppler bubble study 3. Age ≥18 years Exclusion Criteria 1. Stroke mimics, haemorrhagic stroke or cerebral venous thrombosis 2. Subjects with less than 3 months of follow up

Primary outcome measure(s)

  • Recurrent ischemic stroke or transient ischemic attack event within 1 year — Within 1 year
    Ischemic stroke is defined as: Acute focal neurological dysfunction caused by focal infarction at single or multiple sites of the brain or retina. Evidence of acute infarction may come either from A) Symptom duration lasting more than 24 hours B) Neuroimaging or other technique in the clinically relevant area of the brain TIA is defined as: A transient episode of focal neurological dysfunction caused by focal brain or retinal ischemia without acute infarction in the clinically relevant area of the brain or retina. Symptoms should resolve completely within 24 hours.

Trial sites (1)

FacilityCityRegionStatus
National University Hospital Singapore Singapore
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06983795 on ClinicalTrials.gov ↗ ← All trials in Singapore